{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:53:31Z","timestamp":1777103611592,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","award":["A2024138"],"award-info":[{"award-number":["A2024138"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","award":["B2025580"],"award-info":[{"award-number":["B2025580"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515140138"],"award-info":[{"award-number":["2022A1515140138"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jgar.2025.07.016","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T23:12:54Z","timestamp":1753225974000},"page":"356-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prolonged infusion of \u03b2-lactam antibiotics decreases short-term mortality in critically ill patients: A meta-analysis and trial sequential analysis from randomized control trials"],"prefix":"10.1016","volume":"44","author":[{"given":"Baofang","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanchun","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baocheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.07.016_bib0001","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2025.07.016_bib0002","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.016_bib0003","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.diagmicrobio.2014.04.007","article-title":"How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?","volume":"79","author":"Felton","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.016_bib0004","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1164\/rccm.202207-1393OC","article-title":"Antimicrobial exposures in critically ill patients receiving extracorporeal membrane oxygenation","volume":"207","author":"Shekar","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2025.07.016_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02309-18","article-title":"Considerations for dose selection and clinical pharmacokinetics\/pharmacodynamics for the development of antibacterial agents","volume":"63","author":"Rizk","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0006","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.016_bib0007","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus intermittent \u03b2-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials","volume":"194","author":"Roberts","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2025.07.016_bib0008","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.016_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201667","article-title":"Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2025.07.016_bib0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.17219\/acem\/121934","article-title":"Clinical outcomes of continuous vs intermittent meropenem infusion for the treatment of sepsis: a systematic review and meta-analysis","volume":"29","author":"Chen","year":"2020","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.jgar.2025.07.016_bib0011","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock - a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2025.07.016_bib0012","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2025.07.016_bib0013","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/phar.2842","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2025.07.016_bib0014","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jama.2023.10598","article-title":"Continuous vs intermittent meropenem administration in critically ill patients with sepsis: the MERCY Randomized Clinical Trial","volume":"330","author":"Monti","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2025.07.016_bib0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2025.07.016_bib0016","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13613-023-01222-w","article-title":"Prolonged vs intermittent intravenous infusion of \u03b2-lactam antibiotics for patients with sepsis: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis","volume":"13","author":"Li","year":"2023","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jgar.2025.07.016_bib0017","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","article-title":"A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe sepsis","volume":"192","author":"Dulhunty","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2025.07.016_bib0018","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"366","key":"10.1016\/j.jgar.2025.07.016_bib0019","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"28","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2025.07.016_bib0020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE Working Group. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2025.07.016_bib0021","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jgar.2025.07.016_bib0022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jgar.2025.07.016_bib0023","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jgar.2025.07.016_bib0024","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Abdul-Aziz","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2025.07.016_bib0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/antibiotics13030229","article-title":"Efficacy of continuous vs. intermittent administration of cefepime in adult ICU patients with Gram-negative bacilli bacteremia: a randomized double-blind clinical study","volume":"13","author":"\u00c1lvarez-Moreno","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.07.016_bib0026","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10096-016-2819-1","article-title":"Clinical outcomes of extended versus intermittent administration of piperacillin\/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial","volume":"36","author":"Bao","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.016_bib0027","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1186\/cc11405","article-title":"Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial","volume":"16","author":"Chytra","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.jgar.2025.07.016_bib0028","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1128\/AAC.04232-14","article-title":"Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia","volume":"59","author":"Cousson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0029","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkm467","article-title":"Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial. pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection","volume":"61","author":"De Jongh","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0030","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.07.016_bib0031","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/phar.1875","article-title":"Clinical outcomes of extended versus intermittent infusion of piperacillin\/tazobactam in critically ill patients: a prospective clinical trial","volume":"37","author":"SY","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2025.07.016_bib0032","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5414\/CPP43360","article-title":"Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen","volume":"43","author":"Georges","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jgar.2025.07.016_bib0033","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0034","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijantimicag.2014.05.011","article-title":"Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions","volume":"44","author":"Lip\u0161","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"14","key":"10.1016\/j.jgar.2025.07.016_bib0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/TCRM.S145681","article-title":"Selection of piperacillin\/tazobactam infusion mode guided by SOFA score in cancer patients with hospital-acquired pneumonia: a randomized controlled study","volume":"21","author":"Lyu","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jgar.2025.07.016_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2022.154170","article-title":"The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: an assessor-blinded randomized clinical trial","volume":"73","author":"Mirjalili","year":"2023","journal-title":"J Crit Care"},{"key":"10.1016\/j.jgar.2025.07.016_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-12861-7","article-title":"Extended infusion of piperacillin\u2013tazobactam versus intermittent infusion in critically ill Egyptian patients: a cost-efectiveness study","volume":"12","author":"Naiim","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2025.07.016_bib0038","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijantimicag.2006.02.020","article-title":"Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients","volume":"28","author":"Rafati","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.07.016_bib0039","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jac\/dkl478","article-title":"Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study","volume":"59","author":"Roberts","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0040","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jac\/dkp139","article-title":"Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution","volume":"64","author":"Roberts","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0041","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijantimicag.2009.10.008","article-title":"First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis","volume":"35","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.07.016_bib0042","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1128\/AAC.01318-06","article-title":"Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial","volume":"51","author":"Sakka","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0043","first-page":"38","article-title":"Continuous versus intermittent use of meropenem in septic critically ill patients: a randomized controlled trail","volume":"41","author":"Saad","year":"2024","journal-title":"Benha Med J"},{"key":"10.1016\/j.jgar.2025.07.016_bib0044","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4103\/0366-6999.205859","article-title":"Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: a prospective randomized pilot study","volume":"130","author":"Zhao","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jgar.2025.07.016_bib0045","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jiac.2023.05.008","article-title":"Clinical efficacy and safety of prolonged versus intermittent administration of antipseudomonal beta-lactam antibiotics in adults with severe acute infections: a meta-analysis of randomized controlled trials","volume":"29","author":"Kiran","year":"2023","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0046","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/2110-5820-2-37","article-title":"Continuous \u03b2-lactam infusion in critically ill patients: the clinical evidence","volume":"2","author":"Abdul-Aziz","year":"2012","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jgar.2025.07.016_bib0047","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40265-023-01893-6","article-title":"Extended and continuous infusion of novel protected beta-lactam antibiotics: a narrative review","volume":"83","author":"Venuti","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2025.07.016_bib0048","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.2023.6483","article-title":"Do prolonged infusions of beta-lactam antibiotics improve outcomes in critically Ill patients with sepsis?","volume":"330","author":"Shappell","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2025.07.016_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1337570","article-title":"Mortality of continuous infusion versus intermittent bolus of meropenem: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Ai","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2025.07.016_bib0050","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1586\/eri.13.44","article-title":"Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis","volume":"11","author":"Korbila","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2025.07.016_bib0051","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/antibiotics11111508","article-title":"Continuous piperacillin-tazobactam infusion improves clinical outcomes in critically ill patients with sepsis: a retrospective, single-centre study","volume":"11","author":"Hyun","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.07.016_bib0052","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/CCM.0000000000002836","article-title":"Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely ill patients: results of a systematic review and meta-analysis","volume":"46","author":"Rhodes","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2025.07.016_bib0053","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01906-18","article-title":"Optimal piperacillin-tazobactam dosing strategies against extended-spectrum-\u03b2-lactamase-producing enterobacteriaceae","volume":"63","author":"Abodakpi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0054","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/dkaa412","article-title":"Optimizing pharmacokinetics\/pharmacodynamics of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria","volume":"76","author":"Tam","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0055","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01404-23","article-title":"Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin\/tazobactam against extended spectrum beta-lactamase producing Enterobacterales","volume":"68","author":"Cojutti","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.07.016_bib0056","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/clpt.1981.90","article-title":"Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics","volume":"29","author":"Stoeckel","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jgar.2025.07.016_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106856","article-title":"Efficacy of meropenem extended infusion vs. intermittent bolus monotherapy and its combinations with colistin against pseudomonas aeruginosa biofilm","volume":"62","author":"Benavent","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.07.016_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107309","article-title":"Meta-analysis on safety of standard vs. prolonged infusion of beta-lactams","volume":"64","author":"Rolain","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.07.016_bib0059","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1007\/s00134-024-07650-x","article-title":"Continuous infusion of beta-lactam antibiotics in critically ill patients with sepsis: implementation considerations","volume":"50","author":"Barton","year":"2024","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2025.07.016_bib0060","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/ajhp\/60.22.2321","article-title":"Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study","volume":"60","author":"Florea","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jgar.2025.07.016_bib0061","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1592\/phco.21.6.549.34539","article-title":"Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia","volume":"21","author":"McNabb","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2025.07.016_bib0062","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/QCO.0000000000000681","article-title":"Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base","volume":"33","author":"Abdul-Aziz","year":"2020","journal-title":"Curr Opin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:17:15Z","timestamp":1777101435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525001730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":62,"alternative-id":["S2213716525001730"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.07.016","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged infusion of \u03b2-lactam antibiotics decreases short-term mortality in critically ill patients: A meta-analysis and trial sequential analysis from randomized control trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}